| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Research and development expenses | - | - | 411* | |
| General and administrative expenses | - | - | 455* | |
| Intangible asset and goodwill impairment expenses | - | - | 2,420* | |
| Operating loss | - | - | -3,286* | |
| Financial expense (income), net | - | - | 14* | |
| Loss before tax expenses | - | - | -3,272* | |
| Research and development expenses | 443 | 473 | - | |
| General and administrative expenses | 289 | 266 | - | |
| Operating loss | -732 | -739 | - | |
| Tax expenses | - | - | 90* | |
| Financial income, net | -16 | 14 | - | |
| Net loss and comprehensive loss | -748 | -725 | -3,362 | |
| Basic EPS | 0.01 | 0.01 | -0.055 | |
| Diluted EPS | 0.01 | 0.01 | -0.055 | |
| Basic Average Shares | 60,729,100 | 60,729,100 | 60,729,100 | |
| Diluted Average Shares | 60,729,100 | 60,729,100 | 60,729,100 | |
Revium Rx. (RVRC)
Revium Rx. (RVRC)